CVE-2026-108585argocd-mcp through 0.9.0 Path Traversal via delete_application Tool
Updated under an hour ago ()
Does this affect you?
It affects argoproj-labs argocd-mcp. Add what you run to find out whether that includes you.
No exploitation reported and no EPSS estimate yet.
Do this next
Free account, 1 product
argocd-mcp (Argo CD MCP Server) through 0.9.0 contains a path traversal vulnerability in the delete_application tool that allows MCP clients to reach unintended API endpoints via unvalidated applicationName values. Attackers or prompt-injected models can supply dot-segment values like ../repositories/ to send authenticated DELETE requests deleting repositories, clusters, or projects within the token's RBAC permissions.
- CVSS
- 5.4 MEDIUM (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:L
- Weakness (CWE)
- CWE-22
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- VulnCheck
- NVD analysis
- Deferred
- Record last updated
- Oct 14, 2026
- First seen by InfoSec Signals
- Oct 10, 2026
Affected products
argoproj-labs argocd-mcp argoproj_labs:argocd_mcp (from the name) | through 0.9.0 | CNA record |
References
- https://hackmd.io/@haind/argocd-mcp-delete-application-route-smugglingthird-party-advisory
- https://github.com/argoproj-labs/mcp-for-argocd/blob/28d15ca69b0c31387cc6ec73d201fd13c5d22b6a/src/argocd/client.ts#L115-L139technical-description
- https://github.com/argoproj-labs/mcp-for-argocd/blob/28d15ca69b0c31387cc6ec73d201fd13c5d22b6a/src/argocd/http.ts#L86-L91technical-description
- https://github.com/argoproj-labs/mcp-for-argocdproduct
- https://www.vulncheck.com/advisories/argocd-mcp-through-0.9.0-path-traversal-via-delete-application-toolthird-party-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.